Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$553.1 million.

  • Cytokinetics' Cash from Investing Activities fell 57.55% to -$71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.7 million, marking a year-over-year increase of 126.66%. This contributed to the annual value of -$553.1 million for FY2024, which is 331.18% down from last year.
  • Latest data reveals that Cytokinetics reported Cash from Investing Activities of -$553.1 million as of FY2024, which was down 331.18% from $239.3 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Cash from Investing Activities registered a high of $239.3 million during FY2023, and its lowest value of -$553.1 million during FY2024.
  • In the last 3 years, Cytokinetics' Cash from Investing Activities had a median value of -$262.1 million in 2022 and averaged -$192.0 million.
  • As far as peak fluctuations go, Cytokinetics' Cash from Investing Activities soared by 191.27% in 2023, and later plummeted by 331.18% in 2024.
  • Over the past 5 years, Cytokinetics' Cash from Investing Activities (Yearly) stood at -$196.5 million in 2020, then increased by 24.80% to -$147.8 million in 2021, then tumbled by 77.38% to -$262.1 million in 2022, then skyrocketed by 191.27% to $239.3 million in 2023, then crashed by 331.18% to -$553.1 million in 2024.